BACKGROUND: Some evidence suggests that an inadequate vitamin D level may increase the risk for atherosclerotic cardiovascular disease. Whether a low vitamin D level plays a role in venous thromboembolism (VTE), that is, venous thrombosis and pulmonary embolism, is largely unexplored. OBJECTIVES: We tested prospectively, in the Atherosclerosis Risk in Communities (ARIC) cohort, whether the serum level of 25-hydroxyvitamin D (25[OH]D) is inversely associated with VTE incidence, and whether it partly explains the African American excess of VTE in the ARIC Study. PATIENTS AND METHODS: We measured 25(OH)D by using mass spectroscopy in stored samples of 12 752 ARIC Study participants, and followed them over a median of 19.7 years (1990-1992 to 2011) for the incidence of VTE (n = 537). RESULTS: The seasonally adjusted 25(OH)D level was not associated with VTE incidence. In a model adjusted for age, race, sex, hormone replacement therapy, and body mass index, the hazard ratios of VTE across 25(OH)D quintiles 5 (high) to 1 (low) were: 1 (ref.), 0.84 (95% confidence interval [CI] 0.65-1.08), 0.88 (95% CI 0.68-1.13), 1.04 (95% CI 0.78-1.38), and 0.90 (95% CI 0.64-1.27). The lowest 25(OH)D quintile contained 59% African Americans, whereas the highest quintile contained 7% African Americans. However, lower 25(OH)D levels explained little of the 63% greater VTE risk of African Americans over whites in this cohort. CONCLUSIONS: A low 25(OH)D level was not a risk factor for VTE in this prospective study. However, the totality of the literature (three studies) suggests that a low 25(OH)D level might modestly increase VTE risk in whites, but this needs further confirmation.
BACKGROUND: Some evidence suggests that an inadequate vitamin D level may increase the risk for atherosclerotic cardiovascular disease. Whether a low vitamin D level plays a role in venous thromboembolism (VTE), that is, venous thrombosis and pulmonary embolism, is largely unexplored. OBJECTIVES: We tested prospectively, in the Atherosclerosis Risk in Communities (ARIC) cohort, whether the serum level of 25-hydroxyvitamin D (25[OH]D) is inversely associated with VTE incidence, and whether it partly explains the African American excess of VTE in the ARIC Study. PATIENTS AND METHODS: We measured 25(OH)D by using mass spectroscopy in stored samples of 12 752 ARIC Study participants, and followed them over a median of 19.7 years (1990-1992 to 2011) for the incidence of VTE (n = 537). RESULTS: The seasonally adjusted 25(OH)D level was not associated with VTE incidence. In a model adjusted for age, race, sex, hormone replacement therapy, and body mass index, the hazard ratios of VTE across 25(OH)D quintiles 5 (high) to 1 (low) were: 1 (ref.), 0.84 (95% confidence interval [CI] 0.65-1.08), 0.88 (95% CI 0.68-1.13), 1.04 (95% CI 0.78-1.38), and 0.90 (95% CI 0.64-1.27). The lowest 25(OH)D quintile contained 59% African Americans, whereas the highest quintile contained 7% African Americans. However, lower 25(OH)D levels explained little of the 63% greater VTE risk of African Americans over whites in this cohort. CONCLUSIONS: A low 25(OH)D level was not a risk factor for VTE in this prospective study. However, the totality of the literature (three studies) suggests that a low 25(OH)D level might modestly increase VTE risk in whites, but this needs further confirmation.
Authors: Tomasz M Beer; Peter M Venner; Christopher W Ryan; Daniel P Petrylak; Gurkamal Chatta; J Dean Ruether; Kim N Chi; John G Curd; Thomas G DeLoughery Journal: Br J Haematol Date: 2006-09-19 Impact factor: 6.998
Authors: L Moscarelli; M Zanazzi; E Bertoni; L Caroti; G Rosso; S Farsetti; F Annunziata; N Paudice; M Salvadori Journal: Clin Nephrol Date: 2011-05 Impact factor: 0.975
Authors: A E Millen; J Nie; M W Sahli; J A Mares; K J Meyers; B E K Klein; M J LaMonte; P L Lutsey; C A Andrews; R Klein Journal: J Nutr Health Aging Date: 2017 Impact factor: 4.075
Authors: Pamela L Lutsey; Mary R Rooney; Aaron R Folsom; Erin D Michos; Alvaro Alonso; Weihong Tang Journal: Vasc Med Date: 2018-02-05 Impact factor: 3.239
Authors: Stefan Pilz; Nicolas Verheyen; Martin R Grübler; Andreas Tomaschitz; Winfried März Journal: Nat Rev Cardiol Date: 2016-05-06 Impact factor: 32.419
Authors: Marc Blondon; Rebecca J Rodabough; Nicole Budrys; Karen C Johnson; Jeffrey S Berger; James M Shikany; Azad Raiesdana; Susan R Heckbert; JoAnn E Manson; Andrea Z LaCroix; David Siscovick; Bryan Kestenbaum; Nicholas L Smith; Ian H de Boer Journal: Thromb Haemost Date: 2015-02-12 Impact factor: 5.249
Authors: Amy E Millen; Michelle W Sahli; Jing Nie; Michael J LaMonte; Pamela L Lutsey; Barbara E K Klein; Julie A Mares; Kirstin J Meyers; Christopher A Andrews; Ronald Klein Journal: Cardiovasc Diabetol Date: 2016-09-01 Impact factor: 9.951
Authors: Laura P B Elbers; Marije Wijnberge; Joost C M Meijers; Dennis C W Poland; Dees P M Brandjes; Eric Fliers; Victor E A Gerdes Journal: Endocr Connect Date: 2018-01-09 Impact factor: 3.335
Authors: Mara Toderici; María Eugenia de la Morena-Barrio; José Padilla; Antonia Miñano; Ana Isabel Antón; Juan Antonio Iniesta; María Teresa Herranz; Nuria Fernández; Vicente Vicente; Javier Corral Journal: PLoS One Date: 2016-03-22 Impact factor: 3.240